COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00165035
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : August 4, 2011
Conor Medsystems
Information provided by:
Cordis Corporation

Brief Summary:
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent) in the treatment of single-vessel (one blood vessel) and multi-vessel (two or three blood vessels) coronary artery disease.

Condition or disease Intervention/treatment Phase
Coronary Disease Device: CoStar Paclitaxel Drug Eluting Coronary Stent System Device: TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent Phase 3

Detailed Description:
Non -inferiority in 8-month Major Adverse Cardiac Events (MACE) and in-segment late lumen loss at 9 months between the CoStar™ Paclitaxel-Eluting Coronary Stent System and the TAXUS™ Express2™ Drug Eluting Coronary Stent System for the treatment of a single de novo lesion per vessel in patients with single and multi-vessel coronary disease.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1701 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Multi-Center, Single-Blind, Two-Arm, Randomized, Controlled, Non Inferiority Trial of the Conor CoStar Paclitaxel-Eluting Coronary Stent System vs the TAXUS DES in Patients With De Novo Lesions of the Native Coronary Arteries
Study Start Date : May 2005
Actual Primary Completion Date : January 2007
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

Drug Information available for: Paclitaxel

Arm Intervention/treatment
Experimental: 1
CoStar™ Paclitaxel-Eluting Coronary Stent, a reservoir based DES
Device: CoStar Paclitaxel Drug Eluting Coronary Stent System
Drug eluting stent

Active Comparator: 2
TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Device: TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
Drug eluting stent

Primary Outcome Measures :
  1. MACE defined as a composite of target vessel revascularization, new myocardial infarction (MI), or cardiac death [ Time Frame: 8 months ]
  2. In-segment late lumen loss [ Time Frame: 9 months ]

Secondary Outcome Measures :
  1. Device, lesion and procedure success [ Time Frame: At procedure or hospital discharge ]
  2. Incidence of MACE [ Time Frame: 30 days, 9 months and 12 months ]
  3. Coronary angiography in the angiographic cohort [ Time Frame: 9 months ]
  4. Target lesion revascularization [ Time Frame: 8 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

General Inclusion Criteria:

  • Eligible for percutaneous coronary intervention (PCI)
  • Documented stable or unstable angina pectoris (Class I, II, III or IV), documented ischemia, or documented silent ischemia
  • Documented LVEF ≥25% within the last 6 weeks.
  • Eligible for coronary artery bypass graft surgery (CABG)

Exclusion Criteria:

General Exclusion Criteria:

  • Known sensitivity to paclitaxel or polymeric matrices: Translute or PLGA.
  • Planned treatment with any other PCI device in the target vessel(s).
  • MI within 72 hours prior to the index procedure
  • Patient is in cardiogenic shock
  • Cerebrovascular Accident (CVA) within the past 6 months
  • Acute or chronic renal dysfunction (creatinine >2.0 mg/dl or >150 µmol/L)
  • Contraindication to ASA or to clopidogrel
  • Thrombocytopenia
  • Active GI bleeding within past three months
  • Known allergy to stainless steel or cobalt chromium
  • Any prior true anaphylactic reaction to contrast agents
  • Patient is currently taking colchicine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00165035

Layout table for location information
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27705
United States, Ohio
Christ Linder
Cincinatti, Ohio, United States, 45219
Sponsors and Collaborators
Cordis Corporation
Conor Medsystems
Layout table for investigator information
Principal Investigator: Dean J Kereiakes, MD The Christ Hospital, Cincinnati, Ohio
Principal Investigator: Mitchell W Krucoff, MD Duke University Medical Center, Durham, NC
Publications of Results:
Layout table for additonal information
Responsible Party: Mitch W Krucoff, MD, Principal Investigator, Duke University Medical Center Identifier: NCT00165035    
Other Study ID Numbers: COSTAR II
First Posted: September 14, 2005    Key Record Dates
Last Update Posted: August 4, 2011
Last Verified: August 2011
Keywords provided by Cordis Corporation:
Percutaneous coronary intervention (PCI)
Drug eluting stent (DES)
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action